Swedbank increased its holdings in Gilead Sciences (NASDAQ:GILD) by 8.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,930,359 shares of the biopharmaceutical company’s stock after purchasing an additional 143,525 shares during the period. Swedbank’s holdings in Gilead Sciences were worth $138,291,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in GILD. Wafra Investment Advisory Group Inc. NY boosted its holdings in Gilead Sciences by 4.5% in the fourth quarter. Wafra Investment Advisory Group Inc. NY now owns 116,211 shares of the biopharmaceutical company’s stock valued at $8,325,000 after acquiring an additional 4,960 shares during the last quarter. Granite Springs Asset Management LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $201,000. JOYN Advisors Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at $733,000. Ariel Investments LLC boosted its holdings in Gilead Sciences by 3.1% in the fourth quarter. Ariel Investments LLC now owns 2,236,337 shares of the biopharmaceutical company’s stock valued at $160,211,000 after acquiring an additional 66,900 shares during the last quarter. Finally, Aristotle Atlantic Partners LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $6,913,000. 78.35% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

NASDAQ:GILD opened at $74.69 on Tuesday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54. The stock has a market capitalization of $98,075.59, a P/E ratio of 8.73, a price-to-earnings-growth ratio of -1.73 and a beta of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the firm posted $2.70 earnings per share. The company’s revenue was down 18.7% compared to the same quarter last year. equities research analysts predict that Gilead Sciences will post 6.21 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were paid a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s payout ratio is 26.64%.

GILD has been the topic of a number of research analyst reports. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a report on Wednesday, January 17th. Jefferies Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $81.19 to $93.00 in a report on Friday, January 26th. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Mizuho set a $95.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Monday, February 5th. Finally, Maxim Group set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, February 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average price target of $88.61.

In related news, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Friday, April 13th. The stock was sold at an average price of $75.56, for a total value of $440,741.48. Following the transaction, the director now owns 58,452 shares in the company, valued at $4,416,633.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 308,600 shares of company stock worth $24,328,226. Insiders own 1.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2018/04/17/gilead-sciences-gild-stake-raised-by-swedbank.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.